Description: Read the June 2018 issue of Health Watch, published by the Health Section. Practical information for actuaries, articles impact sections, section activities.

Description: A letter from me introducing this issue.

Description: Interview with Paul Ginsburg, president of the Center for Studying Health System Change.

Description: Health Section, Issue 88, February 2019, Health Watch

Description: In this paper, we shine a light on the global public health epidemic of intimate partner violence (IPV). This first paper presents background information on the problem with a focus on health and economic impacts for the actuarial audience

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: Health Section News, August 2005, Issue 50 which discusses the effective management of prescription drug utilization and coverage that continue to represent one of the biggest challenges facing insurers, managed care organizations, employers and consumers alike.

Description: Overview of a benefit rush and its effects on companies.

Description: New and ongoing health projects at the Academy. From Health Watch, May 2008, Issue NO. 58

Description: Part 1 of a 2-part series exploring implementation issues for the Mental Health Parity and Addiction Equity Act of 2008 MHPAEA. Part 2 addresses the new enforcement safe harbor, how the regulations could impact the business of behavioral health care and the impending decisions for payors, employers, providers, and insureds.